In this issue of Cancer Cell, Skrtic et al. demonstrate that inhibition of mitochondrial ribosomes with tigecycline, a known antimicrobial, selectively kills leukemia cells. This finding highlights the metabolic susceptibility of leukemia cells to mitochondrial translational inhibition and identifies a compound with significant efficacy in an in vivo preclinical model
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second- and/or third-ge...
AML cells have unique mitochondrial characteristics such as increased mitochondrial mass, mitochondr...
In this issue of Cancer Cell, Cole and colleagues report a non-mutant mitochondrial protein (ClpP) t...
In this issue of Cancer Cell, Skrtic et al. demonstrate that inhibition of mitochondrial ribosomes w...
SummaryTo identify FDA-approved agents targeting leukemic cells, we performed a chemical screen on t...
Inhibition of mitochondrial translation as a therapeutic strategy for acute myeloid leukemia Ma...
Inhibition of mitochondrial translation as a therapeutic strategy for acute myeloid leukemia Ma...
Recently, we demonstrated that the anti-bacterial agent tigecycline preferentially induces death in ...
Recently, we demonstrated that the anti-bacterial agent tigecycline preferentially induces death in ...
<div><p>Recently, we demonstrated that the anti-bacterial agent tigecycline preferentially induces d...
Recently, we demonstrated that the anti-bacterial agent tigecycline preferentially induces death in ...
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second-and/or third-gen...
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second-and/or third-gen...
In this issue of Blood, Liyanage et al demonstrate that acute myeloid leukemia (AML) cells exhibit ...
Acute myeloid leukemia (AML) cells meet the higher energy, metabolic, and signaling demands of the c...
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second- and/or third-ge...
AML cells have unique mitochondrial characteristics such as increased mitochondrial mass, mitochondr...
In this issue of Cancer Cell, Cole and colleagues report a non-mutant mitochondrial protein (ClpP) t...
In this issue of Cancer Cell, Skrtic et al. demonstrate that inhibition of mitochondrial ribosomes w...
SummaryTo identify FDA-approved agents targeting leukemic cells, we performed a chemical screen on t...
Inhibition of mitochondrial translation as a therapeutic strategy for acute myeloid leukemia Ma...
Inhibition of mitochondrial translation as a therapeutic strategy for acute myeloid leukemia Ma...
Recently, we demonstrated that the anti-bacterial agent tigecycline preferentially induces death in ...
Recently, we demonstrated that the anti-bacterial agent tigecycline preferentially induces death in ...
<div><p>Recently, we demonstrated that the anti-bacterial agent tigecycline preferentially induces d...
Recently, we demonstrated that the anti-bacterial agent tigecycline preferentially induces death in ...
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second-and/or third-gen...
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second-and/or third-gen...
In this issue of Blood, Liyanage et al demonstrate that acute myeloid leukemia (AML) cells exhibit ...
Acute myeloid leukemia (AML) cells meet the higher energy, metabolic, and signaling demands of the c...
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second- and/or third-ge...
AML cells have unique mitochondrial characteristics such as increased mitochondrial mass, mitochondr...
In this issue of Cancer Cell, Cole and colleagues report a non-mutant mitochondrial protein (ClpP) t...